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Zhang et al. evaluated a model of atherosclerosis in which ApoE
knockout (ApoE −/− ) mice were fed a high-fat diet. They found that curcumin inhibited the expression of Toll-like receptor 4 in atherosclerotic plaques, macrophage invasion and NF-kappaB activation in the aorta; reduced the level of inflammatory cytokines and adhesion molecules in the aorta and blood; and reduced the size of atherosclerotic regions, inhibiting their expansion. 19 Ghosh et al. initiated renal failure in LDL receptor knockout mice via partial nephrectomy. They induced atherosclerosis with a high-fat diet and reported that curcumin reduced the area of atherosclerotic lesions by 63%.
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Curcumin and Ischaemic Myocardial Damage
The death of myocytes due to MI temporarily causes an intense inflammatory response via the activation of Toll-like receptors. 21 In a rodent model of MI, considerably increased expression of inflammatory cytokines, such as TNF-alpha, IL-1beta and IL-6, was evident after a few hours in some cases (several hours to 1 day). 22 In addition, the generation of reactive oxygen species due to ischaemia is essential in activating inflammatory responses. 21 Several studies suggest that curcumin has an inhibitory effect on NF-kappaB, which is a pivotal mediator of inflammatory responses.
Lv et al. assessed a rat model of MI in which they ligated the left anterior descending artery. They found that administering 150 mg/ kg curcumin on the day after ligation significantly inhibited an increase in NF-kappaB expression as a result of MI and increased the PPAR-gamma expression, which is involved in anti-inflammatory signalling, consequently reducing the infarct size. 23 In a rabbit model of myocardial ischaemia-reperfusion injury during cardiopulmonary bypass, Saeidinia et al. reported that curcumin inhibited NF-kappaB activation in the nucleus of cardiomyocytes, thus reducing TNFalpha, IL-6 and IL-8 levels in the blood, and that it inhibited monocyte apoptosis. 24 Early growth response 1 plays a key role in the pathophysiology of acute and chronic cardiovascular disease and is associated with induction of TNF-alpha and IL-6 expression. Wang et al. studied a rat model of myocardial ischaemia-reperfusion injury and found that previous administration of curcumin inhibited early growth response 1 expression and reduced the infarct size.
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Curcumin and Myocarditis and Heart Failure
Myocarditis is often induced by a viral infection but has non-infectious causes, including autoimmune disorders. 26, 27 Heart failure is the final stage of cardiovascular disease. Chronic inflammation and subsequent myocyte death are associated with heart failure. Patients with heart failure have an abnormal immune response that disrupts wound healing and prolongs inflammation, consequently worsening heart failure. 28 A high level of the inflammatory cytokine TNF-alpha has been reported in the blood of patients with chronic heart failure. 29 The impact of curcumin in myocarditis has been studied using a number of rodent models. In coxsackievirus B3-induced myocarditis, curcumin inhibited the phosphatidylinositol-3 kinase-Akt-NF-kappaB signalling pathway and inhibited the expression of inflammatory cytokines, such as TNF-alpha, IL-6 and IL-1beta, both systemically and in the myocardium; thus, reducing the inflammatory response. 30 inhibiting myocarditis progression. 32 Morimoto et al. studied two rat models of heart failure caused by hypertension and MI and showed that curcumin inhibits p300 histone acetyltransferase activity, thus inhibiting the development of left ventricular hypertrophy and left ventricular systolic dysfunction. 33 In a rat model of doxorubicin-induced heart failure, curcumin inhibited the expression of atrial natriuretic factor, brain natriuretic peptide and beta-myosin heavy chain. 34 The inhibition of heart failure by curcumin may thus be associated with its anti-inflammatory action. To investigate the effects of curcumin supplementation on systemic inflammation, serum levels of adiponectin and lipid profiles in patients with type 2 diabetes To investigate the efficacy of a novel food-grade freecurcuminoid delivery system in improving markers of hepatic function (inflammation and oxidative stress) in chronic alcoholics
Curcumin and Chronic Obstructive
• 48 subjects with elevated serum transaminase and gamma-glutamyltransferase levels • Placebo or 250 mg curcumin-galactomannoside complex twice daily for 8 weeks IL-6, C-reactive protein, glutathione, superoxide dismutase, glutathione peroxidase Compared to both baseline and the placebo group, curcumin-galactomannoside complex significantly increased levels of glutathione, superoxide dismutase and glutathione peroxidase (p<0.001) and decreased IL-6 and C-reactive protein (p<0.001) Mohammadi et al, 2018 58 To investigate the effects of unformulated curcumin and phospholipidated curcumin on anti-Hsp27 in patients with metabolic syndrome
• 120 patients with metabolic syndrome • 1 g curcumin, phospholipidated curcumin per day or placebo for 6 weeks Anti-Hsp27
Curcumin and phospholipidated curcumin did not modify anti-Hsp27 concentration Vors et al. 2018 59 To investigate: the bioavailability of resveratrol consumed in combination with curcumin after consumption of a high-fat meal; and the acute combined effects of this combination on the postprandial inflammatory response of subjects with abdominal obesity
• 22 healthy subjects • 2 resveratorol/curcumin capsules (100 mg resveratorol sustained-release complex plus 50 mg curcumin sustained-release complex) or placebo (cellulose) before consuming the high-fat meal
Resveratorol/curcumin significantly decreased the cumulative postprandial response of sVCAM-1 compared to placebo (p=0.01) Panahi et al. 2018 60 To evaluate the impact of curcuminoids plus piperine administration on glycaemic, hepatic and inflammatory biomarkers in people with type 2 diabetes
• 100 patients with type 2 diabetes • Curcuminoids 500 mg/day co-administered with piperine 5 mg/day or placebo for 3 months hs-CRP No significant differences in hs-CRP concentrations were observed between curcuminoids and placebo groups Funamoto et al. 2016 40 To evaluate the efficacy of curcumin using dispersion technology in patients with mild COPD by examining its effects on oxidative stress markers and inflammatory markers 
Curcumin, Obesity and Diabetes
Adipose tissue is a multifunctional endocrine organ that releases various inflammatory and anti-inflammatory cytokines and physiologically active peptides. 41, 42 Obesity is a risk factor for cardiovascular disease. 41, 43 The accumulation of pericardial fat and myocardial steatosis is associated with the progression of coronary artery atherosclerosis. In obese patients, the secretion of inflammatory adipocytokines, such as TNF-alpha and IL-6, is increased and the secretion of anti-inflammatory adipocytokines is inhibited in enlarged mast cells in the visceral adipose tissue. 42, 43 Several rodent studies have assessed the effects of curcumin in models of obesity. In a mouse model of obesity due to a high-fat diet and in a model of genetic obesity, curcumin reduced macrophage invasion of adipose tissue, increased adiponectin production (which has anti-inflammatory and anti-atherosclerotic actions) and inhibited adipose tissue inflammation. 44 Pan et al. evaluated a mouse model of obesity due to a high-fat diet and reported that ingestion of curcumin inhibited weight gain, reduced fat accretion due to a high-fat diet and significantly improved the serum lipid profile (including serum levels of triglycerides, total cholesterol, LDL-cholesterol, HDL-cholesterol and free fatty acids). 45 In addition, curcumin increased the adipose triglyceride lipase and hormone-sensitive lipase protein expression by activating PPARgamma/alpha and CCAAT/enhancer binding protein alpha in adipose tissue. Further, curcumin broke down lipids and improved glycolipid metabolism. 45 Curcumin administration via percutaneous absorption in obese rats improved serum leptin levels and reduced adipose tissue volume to a level comparable with that in normal rats. overweight or obese patients who were diagnosed with nonalcoholic steatohepatitis. 47 They noted a decrease in TNF-alpha, high-sensitivity CRP, IL-6 and LDL-cholesterol as well as an increase in HDL-cholesterol in the blood. There was also increased absorption efficiency in patients taking nanocurcumin compared to those taking placebo. Nesfatin, an appetite-regulating protein, is significantly increased in patients taking nanocurcumin. When patients taking placebo were compared with those taking nanocurcumin, the two groups had a similar percentage decrease in BMI, but those taking nanocurcumin had a significantly greater percentage decrease in abdominal circumference. 47 In people with type 2 diabetes, trials have shown that curcumin decreased leptin and increased adiponectin in the blood and resulted in improved lipid metabolism.
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Curcumin and Dementia
Over the past few years, the role of inflammation has been recognised in the onset and progression of dementia. 50, 51 One study reported that dementia onset may be related to conditions such as hypertension, dyslipidaemia and diabetes, independent of cardiovascular risk factors. 52 The onset of Alzheimer's-type dementia is closely correlated with inflammation and oxidative stress in the brain. 50, 53 NF-kappaB activation in the glial cells of Alzheimer's patients induces increased expression of inflammatory cytokines and contributes to neuronal degeneration in the brain. 53 Levels of CRP, IL-6 and alpha1-antichymotrypsin in the blood are significantly correlated with the degree of dementia. 
Trials on Anti-inflammatory Effects of Curcumin
The anti-inflammatory effect of curcumin forms the basis for its potential clinical applications (Figure 2) . Of the 50 completed studies, the 10 randomised double-blind and placebo-controlled comparative studies are listed in Table 1 . The results of eight of these studies were significant. As the absorption of curcumin is very poor, most studies that reported significant effects used a large dose of curcumin (>1.5 g/day) or employed strategies to increase its absorption, such as using a drug delivery system.
Drug Delivery Systems
Curcumin has beneficial effects on the status of various diseases involving chronic inflammation. However, the absorption of curcumin is poor, and even if absorbed into the body it is rapidly metabolised and excreted in faeces. 14 To overcome its low bioavailability, various drug delivery systems have been developed ( Table 2 ). These include polymer nanoparticles, chitosan nanoparticles, colloidal nanoparticles, nanoemulsion and ligand-targeted liposomes.
The beneficial effects of these drug delivery systems on curcumin bioavailability have been reported in streptozotocin-induced diabetic rats, a pulmonary fibrosis rat model, a dextran sulphate sodium-induced inflammatory bowel disease mouse model and a lipopolysaccharidestimulated acute inflammation mouse model. 64 -68 E-selectin-modified liposome was effective for ApoE −/− mice. 69 Moreover, Funamoto et al. reported that curcumin dispersed with colloidal nanoparticles (Theracurmin ® ) suppressed an increase in alpha1-antitrypsin LDL levels in people with mild COPD. 40 The improvement in the bioavailability of curcumin through the development of drug delivery systems may contribute to the successful clinical application of curcumin.
Conclusion
A number of studies have reported the efficacy of curcurmin and the mechanisms by which its anti-inflammatory activity could treat various lifestyle-related conditions associated with chronic inflammation, including atherosclerosis, heart failure, obesity, diabetes and other related diseases, such as dementia. Most of these studies have involved animal experiments; however, there are several reports on the benefits of curcumin use in humans. Because curcumin has extremely low bioavailability in humans, an appropriate drug delivery system is necessary for its clinical application.
It is important to study the relationship between the structure and activity of curcumin and to develop novel compounds that are more effective than natural curcumin. Additional clinical trials involving drug delivery systems for curcumin in humans need to be conducted to determine the benefits of curcumin treatment in conditions associated with inflammation. 
